Cargando…
Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition
Malignant bone disease (MBD) occurs when tumors establish in bone, causing catastrophic tissue damage as a result of accelerated bone destruction and inhibition of repair. The resultant so-called osteolytic lesions (OL) take the form of tumor-filled cavities in bone that cause pain, fractures, and a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255770/ https://www.ncbi.nlm.nih.gov/pubmed/30478297 http://dx.doi.org/10.1038/s41419-018-1203-8 |
_version_ | 1783374012949200896 |
---|---|
author | McNeill, Eoin P. Reese, Robert W. Tondon, Abishek Clough, Bret H. Pan, Simin Froese, Jeremiah Palmer, Daniel Krause, Ulf Loeb, David M. Kaunas, Roland Gregory, Carl A. |
author_facet | McNeill, Eoin P. Reese, Robert W. Tondon, Abishek Clough, Bret H. Pan, Simin Froese, Jeremiah Palmer, Daniel Krause, Ulf Loeb, David M. Kaunas, Roland Gregory, Carl A. |
author_sort | McNeill, Eoin P. |
collection | PubMed |
description | Malignant bone disease (MBD) occurs when tumors establish in bone, causing catastrophic tissue damage as a result of accelerated bone destruction and inhibition of repair. The resultant so-called osteolytic lesions (OL) take the form of tumor-filled cavities in bone that cause pain, fractures, and associated morbidity. Furthermore, the OL microenvironment can support survival of tumor cells and resistance to chemotherapy. Therefore, a deeper understanding of OL formation and MBD progression is imperative for the development of future therapeutic strategies. Herein, we describe a novel in vitro platform to study bone–tumor interactions based on three-dimensional co-culture of osteogenically enhanced human mesenchymal stem cells (OEhMSCs) in a rotating wall vessel bioreactor (RWV) while attached to micro-carrier beads coated with extracellular matrix (ECM) composed of factors found in anabolic bone tissue. Osteoinhibition was recapitulated in this model by co-culturing the OEhMSCs with a bone–tumor cell line (MOSJ-Dkk1) that secretes the canonical Wnt (cWnt) inhibitor Dkk-1, a tumor-borne osteoinhibitory factor widely associated with several forms of MBD, or intact tumor fragments from Dkk-1 positive patient-derived xenografts (PDX). Using the model, we observed that depending on the conditions of growth, tumor cells can biochemically inhibit osteogenesis by disrupting cWnt activity in OEhMSCs, while simultaneously co-engrafting with OEhMSCs, displacing them from the niche, perturbing their activity, and promoting cell death. In the absence of detectable co-engraftment with OEhMSCs, Dkk-1 positive PDX fragments had the capacity to enhance OEhMSC proliferation while inhibiting their osteogenic differentiation. The model described has the capacity to provide new and quantifiable insights into the multiple pathological mechanisms of MBD that are not readily measured using monolayer culture or animal models. |
format | Online Article Text |
id | pubmed-6255770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-62557702018-11-27 Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition McNeill, Eoin P. Reese, Robert W. Tondon, Abishek Clough, Bret H. Pan, Simin Froese, Jeremiah Palmer, Daniel Krause, Ulf Loeb, David M. Kaunas, Roland Gregory, Carl A. Cell Death Dis Article Malignant bone disease (MBD) occurs when tumors establish in bone, causing catastrophic tissue damage as a result of accelerated bone destruction and inhibition of repair. The resultant so-called osteolytic lesions (OL) take the form of tumor-filled cavities in bone that cause pain, fractures, and associated morbidity. Furthermore, the OL microenvironment can support survival of tumor cells and resistance to chemotherapy. Therefore, a deeper understanding of OL formation and MBD progression is imperative for the development of future therapeutic strategies. Herein, we describe a novel in vitro platform to study bone–tumor interactions based on three-dimensional co-culture of osteogenically enhanced human mesenchymal stem cells (OEhMSCs) in a rotating wall vessel bioreactor (RWV) while attached to micro-carrier beads coated with extracellular matrix (ECM) composed of factors found in anabolic bone tissue. Osteoinhibition was recapitulated in this model by co-culturing the OEhMSCs with a bone–tumor cell line (MOSJ-Dkk1) that secretes the canonical Wnt (cWnt) inhibitor Dkk-1, a tumor-borne osteoinhibitory factor widely associated with several forms of MBD, or intact tumor fragments from Dkk-1 positive patient-derived xenografts (PDX). Using the model, we observed that depending on the conditions of growth, tumor cells can biochemically inhibit osteogenesis by disrupting cWnt activity in OEhMSCs, while simultaneously co-engrafting with OEhMSCs, displacing them from the niche, perturbing their activity, and promoting cell death. In the absence of detectable co-engraftment with OEhMSCs, Dkk-1 positive PDX fragments had the capacity to enhance OEhMSC proliferation while inhibiting their osteogenic differentiation. The model described has the capacity to provide new and quantifiable insights into the multiple pathological mechanisms of MBD that are not readily measured using monolayer culture or animal models. Nature Publishing Group UK 2018-11-26 /pmc/articles/PMC6255770/ /pubmed/30478297 http://dx.doi.org/10.1038/s41419-018-1203-8 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article McNeill, Eoin P. Reese, Robert W. Tondon, Abishek Clough, Bret H. Pan, Simin Froese, Jeremiah Palmer, Daniel Krause, Ulf Loeb, David M. Kaunas, Roland Gregory, Carl A. Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition |
title | Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition |
title_full | Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition |
title_fullStr | Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition |
title_full_unstemmed | Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition |
title_short | Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition |
title_sort | three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255770/ https://www.ncbi.nlm.nih.gov/pubmed/30478297 http://dx.doi.org/10.1038/s41419-018-1203-8 |
work_keys_str_mv | AT mcneilleoinp threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT reeserobertw threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT tondonabishek threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT cloughbreth threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT pansimin threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT froesejeremiah threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT palmerdaniel threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT krauseulf threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT loebdavidm threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT kaunasroland threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition AT gregorycarla threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition |